FHTX — Foghorn Therapeutics Share News
0.000.00%
Last trade - 00:00- $118.77m
- -$48.81m
- $30.91m
Brief: Foghorn Therapeutics Q1 EPS USD -0.59
Brief: Foghorn Therapeutics Presents New Preclinical Data On Potential First-In-Class BRM Selective Inhibitor FHD-909 And Selective CBP And Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. reports results for the quarter ended in December - Earnings Summary
Foghorn Therapeutics Inc. expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-S&P Global, Hershey, Under Armour
U.S. STOCKS ON THE MOVE-ConocoPhillips, Advanced Drainage Systems, Molina Healthcare
U.S. STOCKS ON THE MOVE-Kenvue, Tapestry, Ralph Lauren
Foghorn up as Eli Lilly picks its cancer therapy for development
Brief: Foghorn Therapeutics Appoints Stephen Dipalma As Interim CFO
Brief: Foghorn Therapeutics Highlights Clinical Program Updates
Brief: Foghorn Therapeutics Q3 EPS USD -0.34
Foghorn Therapeutics Inc. reports results for the quarter ended in June - Earnings Summary
Brief: Foghorn Therapeutics Q2 EPS USD -0.7
Pfizer, Flagship Pioneering to invest $100 mln in drug discovery (updated)
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery
U.S. RESEARCH ROUNDUP- Ashland, McKesson, Snowflake
Foghorn Therapeutics falls on discontinuing cancer drug trial
Brief: Foghorn Therapeutics Announces Clinical Data From Phase 1 Study Of FHD-286
U.S. STOCKS ON THE MOVE-Spotify, Akero Therapeutics, Cyxtera Technologies